Medicus Pharma Swings from $1.61 Peak to $1.09 after 73% Trial Clearance
Medicus Pharma’s shares jumped to $1.61 before dropping to $1.09 premarket after reporting Phase 2 results showing a 73% clinical and 40% histological clearance rate for its D-MNA treatment in basal cell carcinoma. The company plans an FDA end-of-phase meeting in H1 2026 and a clinical report by Q2 2026.
1. Phase 2 Trial Topline Data
Medicus Pharma reported that its Phase 2 study of D-MNA in nodular basal cell carcinoma enrolled 90 patients, with the 200µg dose cohort achieving a 73% clinical clearance rate and a 40% histological clearance rate. The results provide decision-grade evidence supporting advancement to an end-of-phase meeting with regulators.
2. Shares Volatile on Data Release
Shares jumped to a session high of $1.61 before settling around $1.09 in premarket trade, reflecting both optimism over the trial outcomes and broader momentum indicators showing a neutral RSI at 50.00 and bearish MACD pressure.
3. Upcoming Regulatory and Reporting Agenda
The company aims to convene an FDA end-of-phase meeting in the first half of 2026, followed by a comprehensive Clinical Study Report by Q2 2026 covering safety analyses and procedural observations to inform next-stage development and partnership discussions.